

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-38 (Cancelled)

39. (New) A method for treatment of a psychiatric disorder, disease or condition, which comprises administering to an individual in need of such a treatment an effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

40. (New) A method according to claim 39 wherein said individual is immunized with a therapeutically effective amount of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).

41. (New) The method according to claim 39 wherein said agent is Copolymer 1.

42. (New) The method according to claim 39 wherein said agent is a Copolymer 1-related peptide or a Copolymer 1-related polypeptide.

43. (New) The method according to claim 39 wherein said agent is T cells which have been activated by Copolymer 1.

44. (New) A method according to claim 39 wherein said psychiatric disorder, disease or condition is selected from the group consisting of: (i) anxiety disorders; (ii) mood disorders; (iii) schizophrenia and related disorders; (iv) drug use and dependence; and (v) memory loss disorders.

45. (New) A method according to claim 44 wherein said anxiety disorders include phobic disorders, obsessive-compulsive disorder, stress, post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder.

46. (New) A method according to claim 45 wherein said anxiety disorder is post-traumatic stress disorder (PTSD) and said agent is Copolymer 1.

47. (New) A method according to claim 44 wherein said mood disorders include depression, dysthymic disorder, bipolar disorders and cyclothymic disorder.

48. (New) A method according to claim 44 wherein said psychiatric disorder, disease or condition is schizophrenia and said agent is Copolymer 1.

49. (New) A method according to claim 44 wherein said schizophrenia related disorders include brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and delusional disorder.

50. (New) A method according to claim 44 wherein said drug use and dependence include alcoholism, cocaine dependence, amphetamine dependence, hallucinogen dependence, and phencyclidine use.

51. (New) A method according to claim 44 wherein said memory loss disorder is cognitive impairment.

52. (New) A method according to claim 41 wherein the Copolymer 1 is administered in the form of a vaccine.

53. (New) A method according to claim 52 wherein said vaccine comprises Copolymer 1 without an adjuvant.

54. (New) A method according to claim 52 wherein said vaccine comprises Copolymer 1 emulsified in an adjuvant suitable for human clinical use.

55. (New) A method according to claim 54 wherein said adjuvant is aluminum hydroxide, aluminum hydroxide gel or aluminum hydroxyphosphate.